Ischemic stroke in patients previously anticoagulated for non-valvular atrial fibrillation: Why does it happen?

被引:9
作者
Fernandes, Luis [1 ]
Sargento-Freitas, Joao [2 ]
Milner, James [3 ]
Silva, Alexandra [2 ]
Novo, Ana [2 ]
Goncalves, Tatiana [4 ]
Marinho, Ana Vera [3 ]
Pego, Guilherme Mariano [3 ]
Cunha, Luis [1 ,2 ]
Antonio, Natalia [1 ,2 ]
机构
[1] Univ Coimbra, Fac Med, Coimbra, Portugal
[2] Ctr Hosp & Univ Coimbra, Serv Neurol, Coimbra, Portugal
[3] Ctr Hosp & Univ Coimbra, Serv Cardiol A, Coimbra, Portugal
[4] Ctr Hosp & Univ Coimbra, Serv Med Interna A, Coimbra, Portugal
关键词
Stroke; Anticoagulants; Atrial fibrillation; Treatment; adherence; Administration; oral; ORAL ANTICOAGULANTS; 1ST YEAR; ADHERENCE; DABIGATRAN; PREVENTION; THERAPY; DETERMINANTS; PERSISTENCE; MANAGEMENT;
D O I
10.1016/j.repc.2018.06.004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Oral anticoagulants have proved to be highly effective in preventing atrial fibrillation (AF)-related strokes. The occurrence of stroke despite oral anticoagulation is unexpected and little is known about the mechanisms responsible. The aim of this study was to assess possible mechanisms for stroke occurrence, such as poor treatment adherence and inappropriate dosage, in patients chronically anticoagulated for AF. Methods: We performed a prospective observational study of 60 consecutive patients with non-valvular AF, chronically medicated with an oral anticoagulant and admitted due to ischemic stroke. Treatment adherence was assessed through the Brief Medication Questionnaire (BMQ) and the Medicao da Adesao ao Tratamento (MAT) scales. Patient characteristics, stroke etiology, and appropriacy of anticoagulant dosage were also assessed. Results: Patients' mean age was 78.6 +/- 8.0 years, and 51.7% were male. Overall, the proportion of patients with good adherence to anticoagulants was 63.3%. Adherent patients were more frequently illiterate (26.3% vs. 4.5%, p=0.012). The proportion of patients under vitamin K antagonists (VKAs) with good treatment adherence was significantly higher than that of patients under novel oral anticoagulants (NOACs) (83.3% vs. 54.8%, respectively, for BMQ, p=0.035). However, 91.7% of patients under VKAs presented an admission INR <2. Subtherapeutic prescriptions were found in 43% of patients under NOACs. Conclusion: In the majority of patients, stroke occurrence despite chronic anticoagulation appears to be explained by subtherapeutic dosage, poor treatment adherence or non-cardioembolic etiology, and not by inefficacy of the anticoagulants. (C) 2018 Sociedade Portuguesa de Cardiologia. Published by Elsevier Espana, S.L.U.
引用
收藏
页码:117 / 124
页数:8
相关论文
共 50 条
  • [41] Heart Failure and the Non-Resolution of Atrial Thrombus Detected in Anticoagulated Patients with Non-Valvular Atrial Fibrillation
    Yang, Shu
    Yang, Jie
    Chen, Ning
    Cui, Chang
    Jiao, Jincheng
    Zhu, Li
    Li, Mingfang
    Chen, Minglong
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2025, 31
  • [42] Initiation and continuation of oral anticoagulant prescriptions for stroke prevention in non-valvular atrial fibrillation: A cohort study in primary care in France
    Collings, Shuk-Li
    Vannier-Moreau, Virginie
    Johnson, Michelle E.
    Stynes, Gillian
    Lefevre, Cinira
    Maguire, Andrew
    Asmar, Joelle
    Bizouard, Geoffray
    Duhot, Didier
    Mouquet, Frederic
    Fauchier, Laurent
    ARCHIVES OF CARDIOVASCULAR DISEASES, 2018, 111 (05) : 370 - 379
  • [43] All-Cause, Stroke-, and Bleed-Specific Healthcare Costs: Comparison among Patients with Non-Valvular Atrial Fibrillation (NVAF) Newly Treated with Dabigatran or Warfarin
    Gilligan, Adrienne M.
    Gandhi, Pranav
    Song, Xue
    Wang, Cheng
    Henriques, Caroline
    Sander, Stephen
    Smith, David M.
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2017, 17 (06) : 481 - 492
  • [44] Impact of stroke risk factors on warfarin prescription among patients with non-valvular atrial fibrillation
    Zhao, Yu-Hui
    Zhang, Ting
    Du, Xin
    Wen, Dan
    Shang, Mei-Sheng
    Ma, Chang-Sheng
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (08): : 16587 - 16595
  • [45] Secondary prevention in non-valvular atrial fibrillation patients: a practical approach with edoxaban
    Masjuan, Jaime
    DeFelipe, Alicia
    INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2017, 127 (08) : 716 - 725
  • [46] Temporal trends in ischemic stroke and anticoagulation therapy for non-valvular atrial fibrillation: effect of diabetes
    Shroff, Gautam R.
    Solid, Craig A.
    Bloomgarden, Zachary
    Halperin, Jonathan L.
    Herzog, Charles A.
    JOURNAL OF DIABETES, 2017, 9 (02) : 115 - 122
  • [47] Left atrial dilatation is associated with severe ischemic stroke in men with non-valvular atrial fibrillation
    Kim, Tae-Won
    Jung, Sung-Woo
    Song, In-Uk
    Koo, Jaseong
    Choi, Hyun Seok
    Lee, Kwang-Soo
    Park, Jeong-Wook
    Park, Hun-Jun
    Kim, Joong-Seok
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2015, 354 (1-2) : 97 - 102
  • [48] A Study of Cardiogenic Stroke Risk in Non-valvular Atrial Fibrillation Patients
    Song, Ziliang
    Xu, Kai
    Hu, Xiaofeng
    Jiang, Weifeng
    Wu, Shaohui
    Qin, Mu
    Liu, Xu
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2020, 7
  • [49] Novel Anticoagulants in Prevention of Cardioembolic Stroke in Patiens with Non-Valvular Atrial Fibrillation
    Bauer, Jiri
    CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE, 2013, 76 (05) : 550 - 558
  • [50] New Anticoagulants for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation
    Hoecht, T.
    Frick, M.
    Alber, H.
    Huber, K.
    JOURNAL FUR KARDIOLOGIE, 2012, 19 (3-4): : 55 - 62